Advertisements


Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment

Shares of Aerie Pharmaceuticals Inc. were halted for trading Friday, as the U.S. Food and Drugs Administration reviews a new drug application for .....»»

Category: topSource: marketwatchOct 13th, 2017

Aerie Pharmaceuticals stock halted ahead of announcement of FDA approval of Rhopressa

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchDec 18th, 2017

Spark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye disease

Spark Therapeutics Inc. shares were halted Thursday as a U.S. Food and Drugs Administration advisory committee meets to review the company's gene therapy treatment for patients with vision loss caused.....»»

Category: topSource: marketwatchOct 12th, 2017

HC Wainwright Says Aerpio Pharma Flies Under The Radar Due To OTC Listing, Projects 150% Upside

Aerpio Pharmaceuticals Inc (OTC: ARPO), an OTC-listed company specializing in drug development for ocular diseases, earned a bullish review Wednesday. The interest in the stock can only go higher, as the company seeks to up-list the shares.....»»

Category: blogSource: benzingaApr 21st, 2018

Commit To Purchase Aerie Pharmaceuticals At $40, Earn 13.3% Annualized Using Options

Stock Options Channel.....»»

Category: topSource: redinewsApr 9th, 2018

Incyte"s stock set for selloff, Merck shares drop after disappointing study results of melanoma treatment

Incyte Corp. and Merck & Co. Inc. said an external data monitoring committee (eDMC) determined that results from a phas.....»»

Category: topSource: marketwatchApr 6th, 2018

Arena Pharmaceuticals" stock rockets after positive drug trial results

Shares of Arena Pharmaceuticals Inc. shot up 34% in premarket trade Tuesday, after the drugmaker reported positive results from a phase 2 trial of its treatment for ulcerative colitis. The rally comes a.....»»

Category: topSource: marketwatchMar 20th, 2018

Anthera Pharmaceuticals" stock plummets 85% after CF treatment study disappoints

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchMar 12th, 2018

Progenics shares jump 21% premarket after FDA says it will review treatment for rare cancer

Shares of Progenics Pharmaceuticals Inc. surged 21%.....»»

Category: topSource: marketwatchDec 29th, 2017

DelMar Pharmaceuticals" stock rockets after cancer treatment granted "Fast Track" designation

Shares of DelMar Pharmaceuticals Inc. rocketed 40% in premarket trade Tuesday, after the biopharmaceutical company said its lead-product cancer treatment, VAL-083, was granted "Fast Track" designation by the Food and Drug Administration. "Fa.....»»

Category: topSource: marketwatchDec 26th, 2017

Portola Pharma stock falls 7% after delay in FDA review

Portola Pharmaceuticals Inc. stock fell 7% in late trading Friday afternoon after the company said a regulatory review of a proposed drug would be extended. The Food and Drug Administration asked Portola for more data on a study of the bi.....»»

Category: topSource: marketwatchDec 22nd, 2017

FDA Accepts Allergan and Paratek’s Newest Acne Treatment for Review

Paratek Pharmaceuticals saw its shares make a handy gain on Thursday after the firm announced that the FDA accepted its New Drug Application for the review of Seysara for the treatment of moderate to........»»

Category: blogSource: 247wallstDec 21st, 2017

Ironwood Pharma stock jumps 3.5% on positive trials of treatment for type 2 diabetes

Ironwood Pharmaceuticals Inc. shares surged 3.5% in premarket trade Monday, after the company reported positive results in mid-stage.....»»

Category: topSource: marketwatchDec 4th, 2017

Equifax review exonerates executives" stock sales after data breach

Equifax Inc. (NYSE: EFX) said Friday its board has exonerated four executives who sold company shares after a huge data breach was discovered, but before it was made public. A report by a special committee of Equifax's board concludes that “none .....»»

Category: topSource: bizjournalsNov 6th, 2017

Valeant Surrenders Some Early Gains After FDA Approval Of VYZULTA

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading higher by 22 cents (1.7 percent) at $11.28 in Friday's session. After Thursday's close, the company announced FDA approval of VYZULTA, for the treatment of open angle glaucoma. read more.....»»

Category: blogSource: benzingaNov 3rd, 2017

Pipeline Bomb: Analysts Review Celgene"s Crohn"s Diseases Failure

Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its e.....»»

Category: blogSource: benzingaOct 20th, 2017

Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

Zacks.....»»

Category: topSource: redinewsOct 18th, 2017

Aerie (AERI) Up on FDA Review Committee Result for Rhopressa

Shares of .....»»

Category: dealsSource: nytOct 17th, 2017

With nod from panel, Aerie inches toward FDA approval

Aerie Pharmaceuticals (Nasdaq: AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval. On Friday, an FDA advisory committee voted in favor of .....»»

Category: topSource: bizjournalsOct 13th, 2017

Ethics report says NY lawmaker"s actions warrant review

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017

Ethics panel extends review of New York GOP congressman

The House Ethics Committee says it's extending its review of a congressman whose stock market trades prompted an advocacy group to request an investigation for possible violation of insider trading or conflict of interest laws......»»

Category: topSource: foxnewsOct 12th, 2017